{"id":"NCT00654901","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™","officialTitle":"Immunogenicity Study of the Antibody Persistence and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series of DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Administered at 2, 4, and 6 Months of Age in Healthy Mexican Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2009-05","completion":"2009-07","firstPosted":"2008-04-09","resultsPosted":"2013-06-26","lastUpdate":"2016-05-13"},"enrollment":881,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Pertussis","Hepatitis B","Poliomyelitis","Haemophilus Influenzae Type B Infection"],"interventions":[{"type":"BIOLOGICAL","name":"DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)","otherNames":[]},{"type":"BIOLOGICAL","name":"DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)","otherNames":[]},{"type":"BIOLOGICAL","name":"DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix Hexa™","otherNames":[]}],"arms":[{"label":"DTaP-IPV-Hep B-PRP~T Batch 1","type":"EXPERIMENTAL"},{"label":"DTaP-IPV-Hep B-PRP~T Batch 2","type":"EXPERIMENTAL"},{"label":"DTaP-IPV-Hep B-PRP~T Batch 3","type":"EXPERIMENTAL"},{"label":"Infanrix Hexa™","type":"ACTIVE_COMPARATOR"}],"summary":"This is a follow-up of Study A3L11 (NCT00404651).\n\nImmunogenicity\n\n* To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-Hep B-PRP\\~T or Infanrix hexa™.\n* To describe the immunogenicity of a booster dose of DTaP-IPV-HepB-PRP\\~T in a subset of subjects.\n\nSafety\n\n\\- To describe the safety profile after a booster dose of DTacP-IPV-HepB-PRP\\~T.","primaryOutcome":{"measure":"Geometric Mean Titers of Antibodies Before and After Booster Vaccination With DTaP-IPV-Hep B-PRP~T","timeFrame":"Day 0 (pre-booster) and Day 30 (one month post-booster)","effectByArm":[{"arm":"DTaP-IPV-Hep B-PRP~T Batch 1","deltaMin":91.1,"sd":null},{"arm":"DTaP-IPV-Hep B-PRP~T Batch 2","deltaMin":127,"sd":null},{"arm":"DTaP-IPV-Hep B-PRP~T Batch 3","deltaMin":69.2,"sd":null},{"arm":"Infanrix Hexa™","deltaMin":127,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":4,"countries":["Mexico"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":254},"commonTop":["Solicited Injection Site Pain","Irritability","Solicited Injection Site Erythema","Anorexia","Crying"]}}